دورية أكاديمية
أعرض في EDS

Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.
المؤلفون: Seleme VB; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil. viniciusbseleme@yahoo.com.br.; Positivo University, R. Prof. Pedro Viriato Parigot de Souza, 5300, Curitiba, Paraná, Brazil. viniciusbseleme@yahoo.com.br., Marques GL; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil., Mendes AEM; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil., Rotta I; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil., Pereira M; Department of Cardiology, Hospital Nossa Senhora das Graças, Alcides Munhoz, 433, Curitiba, Paraná, 80810-040, Brazil., Júnior EL; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil., da Cunha CLP; Cardiology-Arterial Hypertension Department, Hospital de Clinicas from Universidade Federal do Parana (HC/UFPR), General Carneiro, 181, Curitiba, Paraná, 80060-900, Brazil.
المصدر: American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2021 Mar; Vol. 21 (2), pp. 165-180.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100967755 Publication Model: Print Cited Medium: Internet ISSN: 1179-187X (Electronic) Linking ISSN: 11753277 NLM ISO Abbreviation: Am J Cardiovasc Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: Auckland, New Zealand : Adis International, c2001-
مواضيع طبية MeSH: Antihypertensive Agents/*therapeutic use , Hypertension/*drug therapy , Nebivolol/*therapeutic use, Adolescent ; Adrenergic beta-Antagonists/therapeutic use ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Calcium Channel Blockers/therapeutic use ; Diabetes Mellitus/epidemiology ; Diuretics/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Hypertension/epidemiology ; Male ; Middle Aged ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Sex Factors ; Socioeconomic Factors ; Young Adult
مستخلص: Introduction: Cardiovascular diseases are the main cause of mortality worldwide, and systemic arterial hypertension is associated with a large number of these cases. The objective of health professionals and health policies should be searching for the best therapeutics to control this disease. A recent consensus indicated that β-blockers have recently lost their place in initial indications for the treatment of systemic arterial hypertension and are now more indicated for the treatment of hypertension in association with other clinical situations such as angina, heart failure and arrhythmia; however, it is known that this approach was based on studies that evaluated older β-blockers such as atenolol.
Objective: The main objective of this study was to perform a systematic review with subsequent meta-analysis on the use of nebivolol for hypertensive disease treatment, comparing it with drugs of the main antihypertensive classes.
Methods: This systematic review was based on a search of the MEDLINE (via Pubmed), Scopus, Cochrane, International Pharmaceuticals Abstracts (IPA), and Lilacs databases for randomized and double-blind clinical trials. In addition, we also searched for gray literature studies, to 31 July 2015. Next, a cumulative meta-analysis was performed, with studies being added in a sequential manner, evaluating their impact on the combined effect. For this project, we only meta-analyzed direct comparisons of random effect.
Results: Overall, 981 clinical trials were included in this systematic review. After careful analysis, 34 randomized and double-blind clinical trials were included to investigate the efficacy of nebivolol on systolic (SBP) and diastolic blood pressure (DBP) control and adverse effects. The study population comprised 12,465 patients with systemic arterial hypertension (SAH) aged between 18 and 85 years; 17% of subjects were of Black ethnicity, approximately 55% were men, and almost 10% had diabetes. In SBP management, nebivolol was superior to other β-blockers and diuretics and showed no difference in efficacy when compared with angiotensin receptor blockers or calcium channel blockers. There were insufficient studies on angiotensin-converting enzyme inhibitors for adequate comparison of both SBP and DBP control. For DBP control, nebivolol was more efficient than other β-blockers, angiotensin receptor blockers, diuretics, and calcium channel blockers.
Discussion: Nebivolol is a third-generation β-blocker with additional capabilities to improve blood pressure levels in patients with arterial hypertension, because it acts by additional mechanisms such as endothelium-dependent vasodilation associated with L-arginine and oxide nitric acid, nitric oxide activity on smooth muscle cells, decreasing platelet aggregation, and leukocyte adhesion in the endothelium, decreasing oxidative stress. Although nebivolol has shown good results in controlling hypertension in this study (with few adverse events when compared with placebo treatment) and has an unquestionable benefit in individuals with heart failure (mainly with reduced ejection fraction), there is a lack of studies proving the benefit of this drug for controlling hypertension and reducing clinical outcomes such as cardiovascular (or general) mortality, acute myocardial infarction, or stroke.
Conclusions: Nebivolol demonstrated at least similar control of blood pressure levels in hypertensive individuals when compared with drugs of the most used classes. In addition, in relation to the control of arterial hypertension, studies with clinical outcomes should be performed to ensure the use of this drug in detriment to others with these well-established results.
References: Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brandão AA, Neves MFT, et al. 7th Brazilian guidelines of hypertension. Arq Bras Cardiol. 2016;107:1–83. (PMID: 278193805319472)
Simão AF, Simão AF, Precoma DB, Andrade JP, Correa FH, Saraiva JF, Sociedade Brasileira de Cardiologia, et al. Brazilian guideline for cardiovascular prevention [in Portuguese]. Arq Bras Cardiol. 2013;101:1–63. (PMID: 24554026)
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC-8). JAMA. 2014;311:507–20. (PMID: 24352797)
Abdulle A, Al-Junaibi, Nagelkerke N. High blood pressure and its association with body weight among children and adolescents in the United Arab Emirates. PLoS One. 2014;9:85129.
World Health Organization. 2018.  https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death . Accessed 9 July 2020.
Holas O, Ezzo D. Nebivolol (bystolic), a novel beta blocker for hypertension. Drug Forecast. 2009;34:188–92.
Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. PLoS One. 2014;9:1–17.
Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–76. (PMID: 28449828)
Ahn J, Kim HJ, Choi JI, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS One. 2017;12:1–13.
Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol. 2008;31:249–52. (PMID: 185433036653554)
Cruikshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol. 2017;956:149–66.
De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010;105:1433–8. (PMID: 20451690)
Richard JR. Beta blockers and the cardiac complications of methamphetamine. Heart Lung Circ. 2017;26:416–7.
Ibanez B, Raposeiras-Roubin S, Garcia-Ruiz JM. The swing of beta-blockers: time for a system reboot. J Am Coll Cardiol. 2017;69:2721–4. (PMID: 28571636)
Bell V, Mitchell GF. Influence of vascular function and pulsatile hemodynamics on cardiac function. Curr Hypertens Rep. 2015;17:1–9.
Cockcroft J. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag. 2007;3:909–17. (PMID: 18200810)
George LB, Jerome DC, Edgar RG. The changing landscape of hypertension and the evolving role of vasodilatory beta-blockers. J Manag Care Pharm. 2007;13:2–24.
Marketou M, Gupta Y, Jain S, Vardas P. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 2017;19:1–10.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Copenhagen: The Cochrane Collaboration; 2011.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41. (PMID: 20171303)
Rotta I. Development and evaluation of a system for the characterization of clinical pharmaceutical services: DEPICT project. Curitiba: Clinics Hospital Library’s from Parana Federal’s University; 2015.
Ursini F, Leporini C, Bene F, D’Angelo S, Mauro D, Russo E, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017;7:5346. (PMID: 287061945509678)
Rotta I. Comparative efficacy and safety of the use of topical antifungal agents in the treatment of dermatomycosis—meta-analysis of randomized clinical trials. Curitiba: Clinics Hospital Library’s from Parana Federal’s University; 2011.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Hoboken: Wiley; 2009.
Dal Negro RW, Tognella S, Mechelleto C. Pharmacokinetics of the effect of nebivolol 5 mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension: a randomized, placebo-controlled study. Clin Drug Investig. 2002;22:197–204.
Dal Negro RW, Tognella S, Pomari C. Once-daily nebivolol 5 mg does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension. Clin Drug Investig. 2002;22:361–7.
Dhakam YZ, McEniery CM, Burton T, Brown MJ, Wilkinson IBA. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351–6. (PMID: 18192850)
Greathouse M. Nebivolol efficacy and safety in patients with stage I–II hypertension. Clin Cardiol. 2010;33:E20–7. (PMID: 201627366653317)
Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension. J Hum Hypertens. 2010;24:64–73. (PMID: 19404314)
Punzi H, Lewin A, Lukíc T, Goodin T, Chen W. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis. 2010;4:349–57. (PMID: 21088095)
Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens. 2007;9:866–75.
Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13:129–40. (PMID: 23519546)
Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9:667–76.
Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens. 2013;15:270–8.
Giles TD, Khan BV, Lato J, Brener L, Ma Y, Lukic T. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial. J Clin Hypertens. 2013;15:687–93.
Lewin A, Punzy H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II Hypertension: results of randomized, placebo-controlled trial. Clin Ther. 2013;35:142–52. (PMID: 23332366)
Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934–42. (PMID: 22493073)
Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14:588–92.
Bhosale VV, Inamdar SC, Karande VB, Burute SR, Murthy MB, Ghatak A. Beneficial effects of nebivolol in comparison with atenolol with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res. 2014;8:HCO1–4.
Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicenter trial. Blood Press Suppl. 2003;12:35–40.
Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–8. (PMID: 12888152)
Pasini AF, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589–96.
Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251–7. (PMID: 18772860)
Susmitha V, Naganjani CV. Comparative study of nebivolol versus atenolol in the treatment of mild and moderate essential hypertension. Int J Pharm Bio Sci. 2013;4:334–8.
Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al. Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148–54. (PMID: 21646599)
Fici F, Celik T, Balta S, Iyisoy A, Unlu M, Demitkol S, et al. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension. J Cardiovasc Pharmacol. 2013;62:388–93. (PMID: 23921307)
Hayek SS, Poole JC, Neuman R, Morris AA, Khayata M, Kavtaradze N, et al. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. J Am Soc Hypertens. 2015;9:206–13. (PMID: 25681236)
Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122–8. (PMID: 21536983)
Sayin MR, Aydin M, Dogan SM, Karabag T, Cetiner MA, Aktop Z. Aortic elastic properties: effects of carvedilol versus nebivolol. Herz. 2012;38:299–305. (PMID: 23263241)
Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Investig. 2012;72:427–32.
Heitmann J, Greulich T, Reinke C, Koehler U, Vogelmeier C, Becker HF, et al. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnea activity in patients with essential hypertension and OSA. Curr Med Res Opin. 2010;26:1925–32. (PMID: 20560730)
Izzo JL, Khan SU, Saleem O, Osmond PJ. Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. J Am Soc Hypertens. 2015;9(7):526–35. (PMID: 261164597457394)
Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18:1060–6. (PMID: 16296572)
Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochrolothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448–56. (PMID: 21602713)
Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, NAC-MD-01 Study Investigators, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomized, multicenter study. Lancet. 2014;383:1889–98. (PMID: 24881993)
Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660–6. (PMID: 1353507)
van Merode T, van Bortel LM, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens. 1989;7:S262–3.
Rosei EA, Rizzoni D, Comini S, Boari G, Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicenter, double-blind study. Blood Press Suppl. 2003;1:30–5. (PMID: 12800985)
Messerli FH, Grossman E, Glodbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998;279:903–7.
Larochelle P, Tobe SW, Lacourciere Y. Beta-blocker in hypertension: studies and meta-analysis over the years. Can J Cardiol. 2014;30:S16–22. (PMID: 24750978)
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;(11):CD002003.
Khan N, Mcalister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174:1737–42. (PMID: 167549041471831)
Law MR, Morris JK, Wald DS. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis of randomized trials in the context of expectations from prospective epidemiological studies. BJM. 2009;338:1665–84.
Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303–9. (PMID: 17280840)
Uhlíř O, Fejfuša M, Havránek K, Lefflerová K, Vojáček J, Widimský J, Winterová J, Zeman K. Nebivolol Versus Metoprolol in the Treatment of Hypertension. Drug Investigation. 1991;3(S1):107–10.
المشرفين على المادة: 0 (Adrenergic beta-Antagonists)
0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Antihypertensive Agents)
0 (Calcium Channel Blockers)
0 (Diuretics)
030Y90569U (Nebivolol)
تواريخ الأحداث: Date Created: 20200726 Date Completed: 20211026 Latest Revision: 20211026
رمز التحديث: 20231215
DOI: 10.1007/s40256-020-00422-0
PMID: 32710438
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-187X
DOI:10.1007/s40256-020-00422-0